ROSATOM delegation took part in the 12th International Symposium on Targeted Alpha Therapy in the Republic of South Africa, ended on March 2, 2023 in Cape Town (South Africa).
The symposium brought together more than 300 nuclear medicine professionals from medical and scientific organizations, educational institutions, pharmaceutical companies, and regulatory authorities from around the world.
The participants of the thematic sections discussed a wide range of vital issues – the results of preclinical and clinical studies of the development of radiopharmaceuticals based on alpha emitters (radioactive isotopes that makes possible the destruction of tumor cells while preserving healthy tissue as much as possible), alpha emitter production technologies, project statuses, quality, regulation and others.
At the symposium, Rosatom experts made poster presentations: “Trends in clinical trials of Ac-225-based (actinium-225) radiopharmaceuticals, the role of Rosatom” and “Ac-225 production quality assurance”. Olga Walzdorf, Head of the Marketing Department at Izotop JSC (belongs to Rusatom Healthcare), spoke about Rosatom’s developments based on actinium-225, as well as about promising areas of its application with Lu-177 (lutetium-177). Representatives of IPPE JSC (State Scientific Centre of the Russian Federation – Leypunsky Institute for Physics and Power Engineering, Joint-Stock Company, belongs to the scientific division of Rosatom) shared their successful experience in the optimization of production processes, which makes it possible to significantly increase isotope production. They spoke about the updated Ac-225 extraction generator system, quality control in the production of alpha emitters, as well as the quality management system that IPPE JSC adopted for the production of radioisotope products in accordance with ISO 9001.
For reference:
ROSATOM is the world leader in the production and supply of actinium-225 radioisotope, one of the most promising alpha-emitters combatting malignant neoplasms. Rosatom’s medical radioisotope products make it possible to perform about 2.5 million diagnostic and therapeutic procedures both in Russia and abroad. The research on actinium-22 applications is underway in more than 50 medical institutions around the world, including a number of clinics in Russia.
